FORM	PTO-1449
(REV	7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OF RECE

COURS O DATES

ATTY. DOCKET NO. 11502/26:1 US

APPLICATION NO. **10/624,315**

INFORMATION DISCLOSURE CITATION (Uses several sheets if necessary)

TITLE: APPARATUS AND METHODS FOR FACILITY REPEATED VASCULAR ACCESS

APPLICANT - Blatter

FILING DATE: July 21, 2003

EXAMINER: (Not yet assigned)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLÁSS	5	SUBCLA	SS	FILING DATE IF APPROPRIATE
XX	1	6,401,721	06/11/02	Maginot			.		11/08/99
	2	6,319,226	11/20/01	Sherry					09/20/99
	3 .	6,293,965	09/25/01	Berg et al.					03/30/00
	4	6,280,460	08/28/01	Bolduc et al.					02/13/98
	5	6,264,633	07/24/01	Knorig					07/09/98
	6	6,261,257	07/17/01	Uffacker et al.					05/24/99
	7	6,254,563	07/03/01	Macoviak et al.					03/20/00
	8	6,248,117	06/19/01	Blatter					04/16/99
	9	6,210,365	04/03/01	Afzal					08/14/98
	10	6,200,257	03/13/01	Winkler					03/24/99
	11	6,171,319	01/09/01	Nobles et al.					04/27/99
	12	6,113,612	09/05/00	Swanson et al.					11/06/98
	13	6,102,884	08/15/00	Squitieri					04/07/97
	14	6,086,553	07/11/00	Akbik					07/01/99
	15	6,068,637	05/30/00	Popov et al.					08/29/96
	16	6,042,569	03/28/00	Finch, Jr. et al.					01/20/98
	17	6,030,392	02/29/00	Dakov					05/19/97
V	18	6,007,576	12/28/99	McClellan					02/06/98
XX	19	5,976,178	11/02/99	Goldsteen et al.					11/07/96
EXAMINER		200	$\overline{\mathcal{M}}$		DATE	CON	SIDERED)	4 Stato5

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DOCUMENT DATE NAME CLASS SUBCLASS FILING DATE

EXAMINER NITIAL		NUMBER					IF APPROPRIAT
$\mathcal{L}_{\mathcal{A}}$	20	5,961,536	10/05/99	Mickley et al.			10/14/97
	21	5,954,706	09/21/99	Sahatjian			06/07/95
	22	5,925,060	07/20/99	Forber	11		03/13/98
	23	5,893,369	04/13/99	LeMole		· · · · · · · · · · · · · · · · · · ·	02/24/97
	24	5,868,770	02/09/99	Rygaard			05/28/97
	25	5,843,027	12/01/98	Stone et al.			12/04/96
	26	5,830,228	11/03/98	Knapp et al.		-	05/29/96
	27	5,830,222	11/03/98	Makower			10/11/96
	28	5,817113	10/06/98	Gifford, III et al.			01/23/97
	29	5,797,934	08/25/98	Rygaard			06/29/95
	30	5,797,879	08/25/98	DeCampli			08/26/96
	31	5,795,325	08/18/98	Valley et al.			12/11/95
	32	5,792,095	08/11/98	Kissinger et al.			07/01/96
	33	5,779,731	07/14/98	Leavitt			12/20/96
	34	5,766,158	06/16/98	Opolski			05/31/96
	35	5,755,775	05/26/98	Trerotola et al.			09/03/96
	36	5,702,412	12/30/97	Popov et al.			10/03/95
	37	5,695,504	12/09/97	Gifford, III et al.			02/24/95
	38	5,693,088	12/02/97	Lazarus			06/07/95
	39	5,662,700	09/02/97	Lazarus			11/18/94
	40	5,662,580	09/02/97	Bradshaw et al.			02/10/95
	41	5,634,936	06/03/97	Linden et al.			02/06/95
4	42	5,620,649	04/15/97	Trotta		7	10/11/95
-SX	43	5,617,878	04/08/97	Taheri	/	/-	05/31/96

EXAMINER Initial if reference considered, whether or not citation is in conformation with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
\sim	44	5,616,114	04/01/97	Thornton et al.			12/08/94
	45	5,613,979	03/25/97	Trotta et al.			11/01/93
	46	5,478,320	12/26/95	Trotta			01/31/94
	47	5,458,568	10/17/95	Racchini et al.			09/17/93
	48	5,456,712	10/10/95	Maginot			10/18/93
	49	5,443,497	08/22/95	Venbrux			11/22/93
	50	5,417,657	05/23/95	Hauer			10/06/93
	51	5,411,475	05/02/95	Atala et al.			04/28/93
	52	5,304,220	04/19/94	Maginot			05/03/93
	53	5,290,306	03/01/94	Trotta et al.			11/29/89
	54	5,102,402	04/07/92	Dror et al.			01/04/91
	55	5,092,841	03/03/92	Spears			05/17/90
	56	4,623,348	11/18/86	Feit			08/13/84
	57	4,846,186	07/11/89	Box et al.			01/12/88
	58	4,819,637	04/11/89	Dormandy, Jr., et al.			09/01/87
	59	4,655,771	04/07/87	Wallsten			04/11/83
	60	4,370,983	02/01/83	Lichtenstein			04/30/79
	61	4,318,401	03/09/82	Zimmerman			04/24/80
	62	4,301,797	11/24/81	Pollack			11/22/78
	63	4,122,858	10/31/78	Schiff			03/23/77
	64	3,991,756	11/16/76	Snyder			08/18/75
	65	3,826,257	06/30/74	Buselmeier	1	1 1	07/14/72
	66	3,395,710	08/06/68	R.A. Stratton et al.			06/14/65
A)	67	3,392,722	07/16/68	R. L. Jorgensen	1 (07/29/65
EXAMINER		and a			DATE CO	NSIDERED	48405

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FOREIGN PA		DOCUMENT	T			SUB-	Trai	ıslation
	REF	NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO
SA	68	WO 98/19629	05/14/98	\wedge				
A	69	WO 98/19634	05/14/98					
EXAMINER					DATE CO	NSIDERED		

[•] EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

-01	١,	Lycos, Your Personal Internet Guide, APHERESIS, located at				
$\langle V_1 \rangle$	'	http://infoplease.lycos.com/ipd/A0321273.html, 1 pg, printed 6/12/03				
(Clark Biocompatible Hemoperfusion System and Block Cutter, Some Other Products from				
1	2	Clark Research, Clark® Biocompatible Hemoperfusion, located at				
ŀ		http://www.clarkrd.com/crd_other2.htm, 10 pgs., printed 6/24/03.				
		HGSA, Medicare Medical Policy Bulletin, Policy S-107: Hemoperfusion, Bulletin, Freedom of				
	3	Information, located at http://www.hgsa.com/professionals/policy/s107.html, 1 pg., printed				
ł		6/24/03.				
		Facts about Plasmapheresis, Plasmapheresis and Autoimmune Disease, MDA Publications,				
	4	located at http://www.mdausa.org/publications/fa-plasmaph.html, 4 pgs., printed 4/16/03.				
	5	Publications, Hemodialysis, located at http://www.rein.ca/hem-e.htm, 4 pgs., printed 4/16/03.				
		Tennessee Kidney Clinics and Affiliates, What is Hemodialysis? located at				
	http://www.dialysisclinics.com/hemo.htlm, 2 pgs., printed 6/24/03					
		Good Nutrition & Hemodialysis, located at				
}	7	http://www.nyu.edu/classes/compnutrfood/Cecilia%20Fong/index.html 1 pg., printed 6/24/03.				
		Mulzer, S.R. and Brash, J.L., Identification of Plasma Proteins Adsorbed to Hemodialyzers				
	8	During Clinical Use, Journal of Biomedical Materials Research, Vol. 23, 1483-1504 (1989)				
		Ljungberg, B., et al., Effective Anticoagulation by a Low Molecular Weight Heparin				
1/	9	(Fragmin®) in Hemodialysis with a Highly Permeable Polysulfone Membrane, Clinical				
		Nephrology, Vol. 38, No. 2-1992 (97-100)				
		Jen Ming Yang, et al., Preparation of Heparin Containing SBS-g-VP Copolymer Membrane for				
10		Biomaterial Usage, Journal of Membrane Science 138 (1998) 19-27				

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CUSTOMER NO. 32642